Candesartan in heart failure
نویسندگان
چکیده
منابع مشابه
Candesartan in heart failure
Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1. It is a prodrug that is converted to its active metabolite during its variable absorption. It is highly protein bound with a small volume of distribution and a nine-hour half-life. Candesartan is one of two angiotensin receptor blockers approved for use in heart failure. MEDLINE was searched using...
متن کاملCandesartan prevented development of diabetes mellitus in heart failure.
M e t h o d s Design: Prespecified secondary analysis of 3 randomized, placebo-controlled trials (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity Program [CHARM]). Allocation: {Concealed}†.* Blinding: Blinded {clinicians, patients, data collectors, outcome assessors, monitoring committee, manuscript writers, and data analysts}†.* Follow-up period: Median 3.1 yea...
متن کاملCandesartan reduced mortality and hospital admissions in chronic heart failure.
and commentary also appear in ACP Journal Club. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . For correspondence: Professor C H A R M-Overall: M A Pfeffer, Brigham and Women’s Hospital, Boston, MA, USA. [email protected] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...
متن کاملCandesartan cilexetil in the treatment of chronic heart failure
The prevalence of heart failure is ever increasing around the world, particularly due to aging populations. Despite improvements in treatment over the last 20 years, the prognosis for heart failure remains poor. Among the treatments recommended for chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are crucial, provided of course that they are not contraindi...
متن کاملEffect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
BACKGROUND Patients with heart failure are at increased risk of sudden death and death attributed to progressive pump failure. We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. METHODS AND RESULTS The CHARM program consisted of 3 component trials that en...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Interventions in Aging
سال: 2006
ISSN: 1176-9092
DOI: 10.2147/ciia.2006.1.4.357